Publications
Full papers
2011
Edwards S.J., Hamilton V., Nherera L., et al. Systematic review of the impact different metal femoral stems (MFSs) have on patient outcomes in total hip replacement (THR) due to osteoarthritis (OA). Value in Health 2011; 14: A245. [FREE full text]
Nherera L., Marks D., Minhas R., et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011; 97: 1175–1181. [FREE full text]
Halpin D.M.G., Gray J., Edwards S.J., et al. Budesonide/formoterol versus salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomized controlled trials. Int. J. Clin. Pract. 2011; 65: 764–774. [Abstract]
Edwards S.J., Wordsworth S., Clarke M.J. Treating pneumonia in critical care in the UK following failure of initial antibiotic: a cost-effectiveness analysis comparing meropenem with piperacillin/tazobactam. Eur. J. Health Econ. 2011; 12: (available online first at: www.springerlink.com/content/q044j5t32601vt4l).
National Collaborating Centre for Women’s and Children Health. Multiple pregnancy: The management of twin and triplet pregnancy in the antenatal period. London, Royal College of Obstetricians and Gynaecologists. 2011. (Nherera L involved in guideline development.) [FREE full text]
2010
Edwards S.J., Borrill J. Network meta-analysis: importance of appropriate trial selection. Value Health 2010; 13: 681–682. [FREE full text]
Edwards S.J., von Maltzahn R., Naya I.P., et al. Budesonide/formoterol for maintenance and reliever therapy: a meta-analysis of randomised controlled trials. Int. J. Clin. Pract. 2010; 64: 619–627. [Abstract]
Gray J., Edwards S.J., Lip G.Y.H. Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomized controlled trials. Curr. Med. Res. Opin. 2010; 26: 537–547. [Abstract]
National Collaborating Centre for Women’s and Children Health. Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. London, Royal College of Obstetricians and Gynaecologists. 2010. (Nherera L involved in guideline development.) [FREE full text]
Nherera L., Calvert N.W., DeMott K., et al. Cost effectiveness analysis of the use of a high intensity statin compared to a low intensity statin in the management of patients with familial hypercholesterolaemia. Curr. Med. Res. Opin. 2010; 26: 529–536. [Abstract]
Visintin C., Mugglestone M.A., Almerie M.Q., et al. On behalf of the Guideline Development Group. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ 2010; 341: c2207. [FREE full text]
2009
Edwards S.J., Clarke M.J., Wordsworth S., et al. Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison. Curr. Med. Res. Opin. 2009; 25: 251–261. [Abstract]
Edwards S.J., Clarke M.J., Wordsworth S., et al. Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. Int. J. Clin. Pract. 2009; 63: 841–854. [FREE full text]
Edwards S.J., Lind T., Lundell L., et al. Systematic review: standard- and double-dose proton pump inhibitors (PPIs) for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomised controlled trials. Aliment. Pharm. Ther. 2009; 30: 547–556. [FREE full text]
Edwards S.J., Smith C.J. Tolerability of atypical antipsychotics in the treatment of schizophrenia and bipolar disorder: a mixed treatment comparison of randomised controlled trials. Clin. Ther. 2009; 31: 1345–1359. [Abstract]
2008
Cooper A., Nherera L., Calvert N., O’Flynn N., et al. Clinical Guidelines and Evidence Review for Lipid Modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease London: National Collaborating Centre for Primary Care and Royal College of General Practitioners. 2008. [FREE full text]
DeMott K., Nherera L., Humphries S.E., et al. Clinical Guidelines and Evidence Review for Familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. National Collaborating Centre for Primary Care and Royal College of General Practitioners. 2008. [FREE full text]
Edwards S.J., Clarke M.J., Wordsworth S., et al. Carbapenems versus other beta-lactams in treating severe infections in intensive care: a systematic review of randomised controlled trials. Eur. J. Clin. Microbiol. 2008; 27: 531–543. [FREE full text]
National Collaborating Centre for Chronic Conditions. Type 2 diabetes (update): national clinical guideline for the management in primary and secondary care. London: Royal College of Physicians, 2008. (Nherera L involved in guideline development). [FREE full text]
2007
Boustead G., Edwards S.J. Systematic review of early compared with deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomised controlled trials. Brit. J. Urol. Int. 2007; 99: 1383–1389. [FREE full text]
Cooper A., Skinner J., Nherera L., et al. Clinical Guidelines and Evidence Review for Post Myocardial Infarction: Secondary prevention in primary and secondary care for patients following a myocardial infarction London: National Collaborating Centre for Primary Care and Royal College of General Practitioners. 2007. [FREE full text]
Edwards S.J., Gruffydd-Jones K., Ryan D.P. Systematic review and meta-analysis of budesonide/formoterol in a single inhaler. Curr. Med. Res. Opin. 2007; 23: 1809–1820. [Abstract]
Minhas R., Cooper A., Walsh JD, et al. Evidence based secondary prevention following a myocardial infarction (MI): the new NICE guideline. Int. J. Clin. Pract. 2007; 61: 1604–1607. [FREE full text]
2006
Edwards S.J., Campbell H.E., Plumb J.M. A cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. Eur. J. Health Econ. 2006; 7: 72–78. [Abstract]
Edwards S.J., Lind T., Lundell L. Proton pump inhibitors for the healing of reflux oesophagitis: a systematic review comparing esomeprazole with other PPIs. Aliment. Pharm. Ther. 2006; 24: 743–750. [FREE full text]
Lip G., Edwards S.J. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb. Res. 2006; 118: 323–333. [Abstract]
National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians, 2006. (Nherera L involved in guideline development) [FREE full text]
National Collaborating Centre for Chronic Conditions. Hypertension: management in adults in primary care: pharmacological update. London: Royal College of Physicians, 2006. (Nherera L involved in guideline development) [FREE full text]
2005
Edwards S.J., Emmas C.E., Campbell H.E. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Curr. Med. Res. Opin. 2005; 21: 785–794. [Abstract]
2003
Raghunath A.S., Green J.R.B., Edwards S.J. A review of the clinical and economic impact of choosing esomeprazole or lansoprazole for the treatment of reflux oesophagitis. Clin. Ther. 2003; 25: 2088–2101. [Abstract]
2002
Edwards S.J., Lind T., Lundell L. Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis. J Drug Ass 2002; 5: 165–178.
Plumb J.M., Edwards S.J. Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis. J Med Econ 2002; 5: 25–38. [Abstract]
2001
Edwards S.J., Lind T., Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment. Pharm. Ther. 2001; 15: 1729–1736. [FREE full text]
Abstracts
2010
Edwards S.J., Gray J. Budesonide/formoterol plus tiotropium (BUD/FORM+TIO) vs salmeterol/fluticasone plus tiotropium (SALM/FLU+TIO): a systematic review and adjusted indirect comparison between two alternative triple treatments in chronic obstructive pulmonary disease (COPD). Value Health 2010; 13: A319.
Edwards S.J., Welton N.J., Borrill J. Gefitinib compared with doublet chemotherapy for first-line treatment non-small-cell lung cancer (NSCLC) a systematic review and adjusted indirect comparison. Value Health 2010; 13: A252–A253.
Edwards S.J., Welton N.J., Borrill J. Tolerability of first-line treatments of locally advanced or metastatic non-small-cell lung cancer (NSCLC) a systematic review and adjusted indirect comparison. Value Health 2010; 13: A250.
Trevor N.C., Tang M., Samuels E.R. Investigating the impact of R&D investment and policy on innovative performance in Europe. Value Health 2010; 13: A423–A424.
Trevor N.C., Alnwick K. How can the use of predictive biomarkers lead to positive HTA recommendations? Value Health 2010; 13: A414.
2009
Borrill J., Edwards S.J., Gray J. Cost-effectiveness of high-dose intravenous proton pump inhibitors (iv PPI) for the prevention of gastric or duodenal ulcer rebleeding after therapeutic endoscopy. Value Health 2009; 12: A347.
Edwards S.J., Gray J., Borrill J. Intravenous (iv) proton pump inhibitors (PPIs) for the treatment of peptic ulcer bleeding (PUB). Value Health 2009; 12: A346.
Meier G., Edwards S.J., von Maltzahn R. Cost-effectiveness of quetiapine extended release versus other atypical antipsychotics in acute bipolar depression. Value Health 2009; 12: A360.
Meier G., Edwards S.J., von Maltzahn R. Efficacy of antipsychotics in the prevention of schizophrenia relapse: a systematic review of double blind randomised controlled trials. Value Health 2009; 12: A351.
2008
Borrill J., Edwards S.J., Patrikios T. Uncontrolled gastro-oesophaageal reflux disease (GORD): findings from a UK multicentre, cross-sectional study. Value Health 2008; 11: A518.
Das RR., Edwards S.J., Emmas C. Patient flow pathway for patients admitted to critical care units with a severe bacterial infection in England. Value Health 2008; 11: A430.
Edwards S.J., Harrison T.W., Naya I.P., et al. Budesonide/formoterol (Symbicort®) for maintenance and reliever therapy (SMART) compared with inhaled corticosteroid (ICS) plus short-acting ß2-agonist (SABA) or alternative ICS and long-acting ß2-agonist (LABA) regimens plus SABA reliever: a systematic review of randomised control trials. Thorax 2008; 63 (Suppl 7): A122.
Edwards S.J., Kingslake S.L. Tolerability of rosuvastatin 40mg compared to 20mg in the treatment of hypercholesterolaemia: evidence from randomised controlled trials. Value Health 2008; 11: A387.
Edwards S.J., Korim F. Tolerability of once-daily extended release quetiapine compared to quetiapine immediate release in the treatment of acute bipolar disorder: an adjusted indirect comparison. Value Health 2008; 11: A581.
Edwards S.J., Korim F. Tolerability of once-daily extended release quetiapine compared to quetiapine immediate release: a meta-analysis of randomised controlled trials in schizophrenia. Value Health 2008; 11: A582.
Payne H., Edwards S.J. Efficacy of leuprorelin 3.75mg compared to 7.5mg in the treatment of prostate cancer: systematic review and meta-analysis. Value Health 2008; 11: A459.
von Maltzahn R., Edwards S.J. Third-generation aromatase inhibitors vs tamoxifen in the treatment of early and advanced breast cancer: a systematic review of randomised controlled trials. Value Health 2008; 11: A459.
2007
Borrill J., Edwards S.J. Cost-effectiveness of esomeprazole in the treatment of adolescent patients with reflux oesophagitis. Value Health 2007; 10: A353–A354.
Edwards S.J., Borrill J. Proton pump inhibitors for the initial treatment of gastroesophageal reflux disease (GORD) symptoms in patients with reflux oesophagitis: a systematic review of randomised controlled trials. Value Health 2007; 10: A352.
Edwards S.J., Hadlow S. Quality of life and tolerability in patients with schizophrenia taking atypical antipsychotics. Euro. Neuropsychopharm. 2007; 17 (Suppl 4): S466.
Nherera L.M., Cooper A., Feder G. Cost effectiveness of comprehensive cardiac rehabilitation and methods used to increase uptake of cardiac rehabilitation after myocardial Infarction. A UK National Health Service perspective. Health Technology Assessment International 16–20 June 2007, Barcelona, Spain.
2006
Edwards S.J., Lind T., Lundell L. Proton pump inhibitors (PPIs) for the healing of reflux oesophagitis: a systematic review of randomised controlled trials. Value Health 2006; 9: 241–242.
2004
Edwards S.J., Hadlow S. Achievement of the European 1998 LDL-C goal by hypercholesterolaemic patients in the STELLAR trial: an evidence-based medicine (EBM) approach. Value Health 2004; 7: 685.
Nherera L., Taylor R. A Systematic Review Of The Efficacy And Safety Of Recombinant Human Growth Hormone (rhGH) In Patients With Aids Associated Weight Loss. Health Technology Assessment International 30 May–2 June 2004, Poland.
Plumb J.M., Edwards S.J. Cost-utility analysis comparing esomeprazole with the oro-dispersible formulation of lansoprazole in the initial treatment of reflux oesophagitis. Value Health 2004; 7: 347.
2003
Edwards S.J. An assessment of the updated results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial: an evidence-based medicine approach. Value Health 2003; 6: 731.
Edwards S.J., Plumb J.M. Meta-analysis of PPI-based triple therapy for the eradication of Helicobacter pylori. Value Health, 2003; 6: 684.
Morrell J., Edwards S. Achievement of the European Atherosclerosis Society LDL-C target by hypercholesterolaemic patients receiving rosuvastatin compared to atorvastatin, pravastatin or simvastatin: an evidence-based medicine approach. Value Health 2003; 6: 310.
Morrell J., Edwards S. Meta-analysis of statins in the lowering of low-density lipoprotein cholesterol to European Atherosclerosis Society target using rosuvastatin as a common comparator. Value Health 2003; 6: 309.
Plumb J.M., Edwards S.J. Cost-effectiveness analysis of proton pump inhibitors in the maintenance of healed reflux oesophagitis. Gut 2003; 52 (Suppl 1): A44.
Plumb J.M., Edwards S.J. Cost-minimisation analysis of PPI-based triple therapy for the eradication of Helicobacter pylori. Value Health 2003; 6: 686.
2002
Edwards S. Meta-analysis of esomeprazole 40 mg and lansoprazole 30 mg in the healing of reflux oesophagitis. Value Health 2002; 5: 503.
Edwards S., Wahlqvist P. Effectiveness of medical interventions in patients with symptoms of GERD — a systematic review. Value Health 2002; 5: 250.
2001
Nherera L.M., Kumaranayake L., Hongoro C. "How can we improve access to and coverage of Health Services using Private Health Insurance Schemes in Zimbabwe"? International Health Economics Association 22–25 July 2001, York, United Kingdom.
